AU Patent

AU2021391452A1 — Small molecule inhibitor of cathepsin c and medicinal use thereof

Assigned to Reistone Biopharma Co Ltd · Expires 2023-06-29 · 3y expired

What this patent protects

The present disclosure relates to a small molecule inhibitor of cathepsin C and the medicinal use thereof. Specifically, provided in the present disclosure are an amide nitrile compound represented by formula VI, a pharmaceutical composition containing the compound, and the use t…

USPTO Abstract

The present disclosure relates to a small molecule inhibitor of cathepsin C and the medicinal use thereof. Specifically, provided in the present disclosure are an amide nitrile compound represented by formula VI, a pharmaceutical composition containing the compound, and the use thereof in the inhibition of cathepsin C.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021391452A1
Jurisdiction
AU
Classification
—
Expires
2023-06-29
Drug substance claim
No
Drug product claim
No
Assignee
Reistone Biopharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.